Loading
A phase 1/2 trial of PM8002 in advanced solid tumours, run by Biotheus Inc., now recruiting.
PM8002 in the Treatment of Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05918445 by Biotheus Inc., with 380 participants planned, started 2021-03-09 and due to reach its primary completion in 2025-11-30. Interventions recorded: PM8002.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares PM8002, BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares BioNTech, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/